There is a growing amount of evidence, in the form of small clinical trials, series of patients and case reports, that cannabinoids could be efficient in the treatment of neuropathic pain. The cannabinoids most often evaluated have been Δ9 tetrahydrocannabinol (THC) administered by oral route and extracts of cannabis with different proportions of THC and cannabidiol administered by oral or sublingual route. Canada has recently approved an extract of cannabis which is administered by sublingual route for the treatment of this type of pain in patients with MS. Nevertheless, it will be necessary to wait for the publication of the results of ongoing clinical trials with cannabis extracts by oral and sublingual route to precisely define their position in the therapeutic arsenal for the treatment of neuropathic pain.
|Publication status||Published - 1 Dec 2005|
- Δ tetrahydrocannabinol 9
- Neuropathic pain